{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:16:10Z","timestamp":1740125770080,"version":"3.37.3"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T00:00:00Z","timestamp":1485734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T00:00:00Z","timestamp":1485734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Cancer Care"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1111\/ecc.12638","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T13:12:57Z","timestamp":1485781977000},"page":"e12638","source":"Crossref","is-referenced-by-count":5,"title":["Long-term safety of monthly zoledronic acid therapy beyond 1\u00a0year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study"],"prefix":"10.1155","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-3311","authenticated-orcid":false,"given":"A.A.","family":"Khalafallah","sequence":"first","affiliation":[{"name":"Launceston General Hospital; Launceston TAS. Australia"},{"name":"Menzies Research Institute; Faculty of Health Sciences; University of Tasmania; Launceston TAS. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Slancar","sequence":"additional","affiliation":[{"name":"Haematology & Oncology Clinics of Australia - Southport; Southport Qld Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Cosolo","sequence":"additional","affiliation":[{"name":"John Fawkner Cancer Trial Centre; Coburg Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Abdi","sequence":"additional","affiliation":[{"name":"Griffith University; The Tweed Hospital; Tweed Heads NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Chern","sequence":"additional","affiliation":[{"name":"Redcliffe Hospital; Redcliffe Qld Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.J.","family":"Woodfield","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Australia Pty Ltd; North Ryde NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Copeman","sequence":"additional","affiliation":[{"name":"Manly Hospital; Manly NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,30]]},"reference":[{"issue":"34","key":"10.1111\/ecc.12638-BIB0002|ecc12638-cit-0002","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1111\/ecc.12638-BIB0003|ecc12638-cit-0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"Oncologist"},{"issue":"8","key":"10.1111\/ecc.12638-BIB0004|ecc12638-cit-0004","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.revmed.2010.11.007","article-title":"Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma","volume":"32","author":"Brantus","year":"2011","journal-title":"La Revue de M\u00e9decine Interne"},{"issue":"7","key":"10.1111\/ecc.12638-BIB0005|ecc12638-cit-0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12094-012-0832-0","article-title":"SEOM guidelines for the treatment of bone metastases from solid tumours","volume":"14","author":"Cassinello Espinosa","year":"2012","journal-title":"Clinical and Translational Oncology"},{"issue":"10","key":"10.1111\/ecc.12638-BIB0006|ecc12638-cit-0006","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3109\/07357900902783203","article-title":"Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer","volume":"27","author":"Crawford","year":"2009","journal-title":"Cancer Investigation"},{"issue":"9","key":"10.1111\/ecc.12638-BIB0007|ecc12638-cit-0007","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1111\/ecc.12638-BIB0008|ecc12638-cit-0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1111\/ecc.12638-BIB0009|ecc12638-cit-0009","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1111\/ecc.12638-BIB0010|ecc12638-cit-0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"The Lancet Oncology"},{"issue":"21","key":"10.1111\/ecc.12638-BIB0011|ecc12638-cit-0011","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1111\/ecc.12638-BIB0012|ecc12638-cit-0012","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"Journal of Bone and Mineral Research"},{"issue":"15","key":"10.1111\/ecc.12638-BIB0013|ecc12638-cit-0013","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1111\/ecc.12638-BIB0014|ecc12638-cit-0014","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1111\/ecc.12638-BIB0015|ecc12638-cit-0015","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00520-008-0484-3","article-title":"Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: How the knowledge of a phenomenon can change its evolution","volume":"16","author":"Verde","year":"2008","journal-title":"Supportive Care in Cancer"},{"issue":"8","key":"10.1111\/ecc.12638-BIB0016|ecc12638-cit-0016","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"issue":"11","key":"10.1111\/ecc.12638-BIB0017|ecc12638-cit-0017","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"issue":"9757","key":"10.1111\/ecc.12638-BIB0018|ecc12638-cit-0018","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"The Lancet"},{"issue":"23","key":"10.1111\/ecc.12638-BIB0019|ecc12638-cit-0019","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1111\/ecc.12638-BIB0020|ecc12638-cit-0020","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.22504","article-title":"The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"10.1111\/ecc.12638-BIB0021|ecc12638-cit-0021","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Poznak","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1111\/ecc.12638-BIB0022|ecc12638-cit-0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1111\/ecc.12638-BIB0023|ecc12638-cit-0023","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"19","key":"10.1111\/ecc.12638-BIB0024|ecc12638-cit-0024","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1111\/ecc.12638-BIB0025|ecc12638-cit-0025","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1111\/ecc.12638-BIB0026|ecc12638-cit-0026","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1111\/ecc.12638-BIB0027|ecc12638-cit-0027","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ecc.12638\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:11:10Z","timestamp":1671541870000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ecc.12638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,30]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1111\/ecc.12638","archive":["Portico"],"relation":{},"ISSN":["0961-5423"],"issn-type":[{"type":"print","value":"0961-5423"}],"subject":[],"published":{"date-parts":[[2017,1,30]]}}}